Natalya M Kogan

Title: Natalya M Kogan: Innovator in Cannabinoid Therapeutics

Introduction

Natalya M Kogan is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of cannabinoid research, particularly in the development of therapeutic compounds. Her work focuses on the medical applications of cannabinoic quinones, which have the potential to treat various disorders.

Latest Patents

Kogan holds a patent for "Compositions including quinonoid derivatives of cannabinoids for therapeutic use." This invention relates to cannabinoic quinone compounds, specifically five cannabinoic quinones designated as HU-331, HU-336, HU-345, HU-395, and HU-396. These compounds are described as active agents in pharmaceutical compositions aimed at treating inflammatory, infectious, auto-immune, and hyperproliferative disorders. The compounds may serve as anti-tumor agents or for cancer treatment. Notably, HU-345, HU-395, and HU-396 are recognized as novel cannabinoic quinones.

Career Highlights

Kogan is affiliated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Her innovative work has positioned her as a key figure in cannabinoid research, contributing to advancements in therapeutic applications.

Collaborations

Kogan has collaborated with notable researchers in her field, including Raphael Mechoulam and Ruth Rabinowitz. These partnerships have furthered the understanding and development of cannabinoid-based therapies.

Conclusion

Natalya M Kogan's contributions to cannabinoid therapeutics highlight her role as an influential inventor in the medical field. Her patented innovations pave the way for potential treatments for serious health conditions.